WallStreetZenWallStreetZen

NASDAQ: CMMB
Chemomab Therapeutics Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CMMB

Based on 1 analyst offering 12 month price targets for Chemomab Therapeutics Ltd

Min Forecast
$25.00+639.64%
Avg Forecast
$25.00+639.64%
Max Forecast
$25.00+639.64%

Should I buy or sell CMMB stock?

Based on 1 analyst offering ratings for Chemomab Therapeutics Ltd.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CMMB's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates CMMB as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their CMMB stock forecasts and price targets.

CMMB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-27

1 of 1

Forecast return on equity

Is CMMB forecast to generate an efficient return?

Company
-4,266.95%
Industry
91.11%
Market
-63.07%
CMMB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CMMB forecast to generate an efficient return on assets?

Company
-3,718.67%
Industry
35.85%
CMMB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CMMB earnings per share forecast

What is CMMB's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.60
Avg 2 year Forecast
-$1.00
Avg 3 year Forecast
-$0.80

CMMB revenue forecast

What is CMMB's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$243.4M
Avg 2 year Forecast
$134.4M
Avg 3 year Forecast
$355.6M

CMMB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CMMB$3.38$25.00+639.64%Buy
BLRX$3.84$19.00+394.79%Strong Buy
EDSA$2.54$5.00+96.85%Buy
CURX$0.67N/AN/A
ICU$0.64N/AN/A
View Top Biotech Stocks

Chemomab Therapeutics Stock Forecast FAQ

Is Chemomab Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CMMB) stock is to Buy CMMB stock.

Out of 1 analyst, 0 (0%) are recommending CMMB as a Strong Buy, 1 (100%) are recommending CMMB as a Buy, 0 (0%) are recommending CMMB as a Hold, 0 (0%) are recommending CMMB as a Sell, and 0 (0%) are recommending CMMB as a Strong Sell.

If you're new to stock investing, here's how to buy Chemomab Therapeutics stock.

What is CMMB's earnings growth forecast for 2025-2027?

(NASDAQ: CMMB) Chemomab Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.54%.

Chemomab Therapeutics's earnings in 2025 is -$11,826,000.On average, 1 Wall Street analyst forecast CMMB's earnings for 2025 to be -$248,310,684, with the lowest CMMB earnings forecast at -$248,310,684, and the highest CMMB earnings forecast at -$248,310,684. On average, 1 Wall Street analyst forecast CMMB's earnings for 2026 to be -$413,851,140, with the lowest CMMB earnings forecast at -$413,851,140, and the highest CMMB earnings forecast at -$413,851,140.

In 2027, CMMB is forecast to generate -$331,080,912 in earnings, with the lowest earnings forecast at -$331,080,912 and the highest earnings forecast at -$331,080,912.

What is CMMB's revenue growth forecast for 2029-2031?

(NASDAQ: CMMB) Chemomab Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.62%.

Chemomab Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CMMB's revenue for 2029 to be $100,714,813,430, with the lowest CMMB revenue forecast at $100,714,813,430, and the highest CMMB revenue forecast at $100,714,813,430. On average, 1 Wall Street analysts forecast CMMB's revenue for 2030 to be $55,617,454,705, with the lowest CMMB revenue forecast at $55,617,454,705, and the highest CMMB revenue forecast at $55,617,454,705.

In 2031, CMMB is forecast to generate $147,161,326,873 in revenue, with the lowest revenue forecast at $147,161,326,873 and the highest revenue forecast at $147,161,326,873.

What is CMMB's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CMMB) forecast ROA is -3,718.67%, which is lower than the forecast US Biotechnology industry average of 35.85%.

What is CMMB's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CMMB price target, the average CMMB price target is $25.00, with the highest CMMB stock price forecast at $25.00 and the lowest CMMB stock price forecast at $25.00.

The Wall Street analyst predicted that Chemomab Therapeutics's share price could reach $25.00 by Aug 27, 2026. The average Chemomab Therapeutics stock price prediction forecasts a potential upside of 639.64% from the current CMMB share price of $3.38.

What is CMMB's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CMMB) Chemomab Therapeutics's current Earnings Per Share (EPS) is -$3.12. On average, analysts forecast that CMMB's EPS will be -$0.60 for 2025, with the lowest EPS forecast at -$0.60, and the highest EPS forecast at -$0.60. On average, analysts forecast that CMMB's EPS will be -$1.00 for 2026, with the lowest EPS forecast at -$1.00, and the highest EPS forecast at -$1.00. In 2027, CMMB's EPS is forecast to hit -$0.80 (min: -$0.80, max: -$0.80).

What is CMMB's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CMMB) forecast ROE is -4,266.95%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.